Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share Dump

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Jan 28, 2021 11:20am

199 Views

Post# 32409461

RE:RE:Share Dump

I was thinking the same thing too. GME aparently lost something like $400m last year. Buying a company that is losing money for 3x what it went for a week ago only makes sense if you think their fortunes will dramatically change.

You might beat the shorts in that scenario in the short term, but eventually it will catch up with you. Hence todays price drops in GME and others.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project